New cocktail of drugs aims to boost stomach cancer treatment
NCT ID NCT07294664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding an extra drug (either SHR2554 or apatinib) to standard immunotherapy plus chemotherapy can help people with advanced gastric cancer who don't get enough benefit from current treatments. About 78 adults with stage III or IV stomach cancer will receive the combination. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR1701 (an immunotherapy drug) combined with chemotherapy (CAPOX) and either SHR2554 (an EZH2 inhibitor) or apatinib (an anti-angiogenic drug)
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with advanced gastric cancer who don't respond well to standard immunotherapy plus chemotherapy.
What could go wrong
This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. Adding more drugs also increases the risk of side effects, and the combination may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••